- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06143397
Effect of TTNS and PNS on Neurogenic Overactive Bladder Symptoms in Female Patients With Multiple Sclerosis.
November 26, 2025 updated by: Busra Aydin Erkilic, Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Effect of Transcutaneous Posterior Tibial Nerve Stimulation and Parasacral Transcutaneous Electrical Stimulation on Neurogenic Overactive Bladder Symptoms in Female Patients With Multiple Sclerosis.
This study aims to evaluate the use of transcutaneous tibial nerve stimulation (TTNS) and parasacral nerve stimulation (PSS) methods in the treatment of overactive bladder (OAB) symptoms in patients with Multiple Sclerosis (MS), including urination frequency, urgency, urinary incontinence, post-void residue, maximum micturition rate.
To investigate the effect on parameters such as voiding volume and quality of life and to compare the final results between groups.
Study Overview
Status
Completed
Conditions
Detailed Description
Participants will be divided into 3 groups: TTNS, PNS, and placebo groups, and all participants will be given behavioral treatment.
Tibial nerve stimulation will be given to the TTNS group, sacral nerve stimulation will be given to the PNS group, and sham current will be given to the placebo group.
Stimulation treatments will be applied 2 days a week for 30 minutes each for 6 weeks.
Participants will be evaluated before and after treatment.
The parameters of urination frequency, urgency, and urinary incontinence will be evaluated with a 3-day voiding diary (BD), maximum flow rate (Qmax), time to reach maximum flow (TQmax), average flow rate, flow time (Tw), voiding time and voiding volume (VV) values will be evaluated by uroflowmetry, post-voiding residual (PVR) volume will be evaluated by ultrasound, and quality of life will be evaluated by King's Quality of Life Questionnaire (KHQ); Expanded Disability Status Scale (EDSS), Overactive bladder form (OAB-v8), Incontinence Severity Index (ISI), Neurogenic Bladder Symptom Score (NBSS) will be recorded.
Study Type
Interventional
Enrollment (Actual)
42
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Istanbul, Turkey (Türkiye)
- Prof.Dr.Cemil Taşcıoğlu Şehir Hastanesi
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Having symptoms related to overactive bladder (OAB-v8 score ⩾8),
- Over 18 years of age
- No relapse for at least 1 month
- All types of MS, including those with relapses
- Female MS patients with an Expanded Disability Status Scale (EDSS) score below 7.0
- Agreeing to participate in the research
Exclusion Criteria:
- Patients with urinary tract infections
- Patients diagnosed with diabetes mellitus
- Patients using diuretic drugs or patients with a clean intermittent catheter
- Patients with a history of different urological diseases
- Patients with heart or brain pacemaker users, those with epilepsy, and patients with language and cognitive limitations
- Patients who are pregnant or in the postpartum period
- Lack of activity performance for 2 weeks (regardless of which group)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Sham Comparator: Sham stimulation
|
It includes techniques and skills to prevent incontinence and restrain the urge to urinate.
It also includes lifestyle interventions such as losing weight, relieving constipation, quitting smoking, reducing caffeine, managing uric acid, wearing non-restrictive, easily removable clothing, reducing emotional stress, and correcting faulty frequent urination by introducing avoidance and distraction techniques.
Additionally, advice on proper voiding position and an exercise protocol will be given.
The exercise protocol will include three sets of 8-10 near-maximal contractions in lying, sitting and standing positions.
Each contraction will be based on the endurance of the pelvic floor muscles and the participant will aim to hold the muscles for 10 seconds.
They will be told to do it twice a day, morning and evening.
Participants will perform the behavioral training protocol at home.
Electrodes will be placed in three areas simultaneously.
These regions are the tibial and parasacral locations and the scapular region, with a distance of approximately 4 cm between the electrodes.
Of these three regions, only the channel to the scapular region will be activated, the remaining two regions will be closed.
Regarding the sham group, the parameters used in the scapular region will be applied with a frequency of 100 Hz, a pulse duration of 100 μs, and 30 minutes.
This configuration is known as conventional transcutaneous electrical nerve stimulation and is commonly used for non-invasive and non-pharmacological treatment of pain.Stimulation will be applied 2 days a week, each application for 30 minutes, for 6 weeks.
|
|
Experimental: TTNS (Transcutaneous tibial nerve stimulation)
|
Electrodes will be placed in two areas simultaneously (posterior tibial nerve and parasacral locations).
Only the electrodes going to the tibial region will be activated, the parasacral electrodes will not be active.
A Biolito (MTR+Vertriebs GmbH, Berlin) stimulator will be used to perform posterior tibial nerve stimulation.
Stimulation will be delivered via two 50 mm x 50 mm adhesive electrode pads under the left medial malleolus and 5 cm proximal to the distal electrode.
Appropriate electrode site will be confirmed by the presence of big toe plantar flexion during stimulation (stimulus intensity will be adjusted according to the patient's tolerance for 200 μs duration at 10 Hz frequency).
Stimulation will be applied 2 days a week, each application for 30 minutes, for 6 weeks.
It includes techniques and skills to prevent incontinence and restrain the urge to urinate.
It also includes lifestyle interventions such as losing weight, relieving constipation, quitting smoking, reducing caffeine, managing uric acid, wearing non-restrictive, easily removable clothing, reducing emotional stress, and correcting faulty frequent urination by introducing avoidance and distraction techniques.
Additionally, advice on proper voiding position and an exercise protocol will be given.
The exercise protocol will include three sets of 8-10 near-maximal contractions in lying, sitting and standing positions.
Each contraction will be based on the endurance of the pelvic floor muscles and the participant will aim to hold the muscles for 10 seconds.
They will be told to do it twice a day, morning and evening.
Participants will perform the behavioral training protocol at home.
|
|
Experimental: PNS (Parasacral nerve stimulation)
|
It includes techniques and skills to prevent incontinence and restrain the urge to urinate.
It also includes lifestyle interventions such as losing weight, relieving constipation, quitting smoking, reducing caffeine, managing uric acid, wearing non-restrictive, easily removable clothing, reducing emotional stress, and correcting faulty frequent urination by introducing avoidance and distraction techniques.
Additionally, advice on proper voiding position and an exercise protocol will be given.
The exercise protocol will include three sets of 8-10 near-maximal contractions in lying, sitting and standing positions.
Each contraction will be based on the endurance of the pelvic floor muscles and the participant will aim to hold the muscles for 10 seconds.
They will be told to do it twice a day, morning and evening.
Participants will perform the behavioral training protocol at home.
Electrodes will be placed in two areas simultaneously (posterior tibial nerve and parasacral locations).
Only the electrodes going to the parasacral region will be activated, the tibial electrodes will not be active.
For parasacral region stimulation, electrodes will be positioned symmetrically in the parasacral region under the posterior superior iliac spines to stimulate the S2 and S3 nerve roots.
A duration of 200 μs at a frequency of 10 Hz will be set with the Biolito (MTR+Vertriebs GmbH, Berlin) stimulator.
The intensity level will be adjusted according to the tolerance of the patient.
Stimulation will be applied 2 days a week, each application for 30 minutes, for 6 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Uroflowmetry
Time Frame: Baseline
|
It provides a valuable non-invasive assessment of voiding functions.
It is the measurement of urine flow rate in ml/sec with the help of a flow meter.
Since it is non-invasive among urodynamic tests, it can be used for screening purposes.
Pattern and rate of flow depend on detrusor function and bladder outlet resistance.
|
Baseline
|
|
Uroflowmetry
Time Frame: After the 6-week intervention
|
It provides a valuable non-invasive assessment of voiding functions.
It is the measurement of urine flow rate in ml/sec with the help of a flow meter.
Since it is non-invasive among urodynamic tests, it can be used for screening purposes.
Pattern and rate of flow depend on detrusor function and bladder outlet resistance.
|
After the 6-week intervention
|
|
Post voiding residue (PVR)
Time Frame: Baseline
|
PVR will be measured using a 5-13-MHz convex ultrasound probe.
|
Baseline
|
|
Post voiding residue (PVR)
Time Frame: After the 6-week intervention
|
PVR will be measured using a 5-13-MHz convex ultrasound probe.
|
After the 6-week intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overactive bladder form (OAB-v8)
Time Frame: Baseline
|
OAB-v8 is an eight-item screening test for overactive bladder (OAB) symptoms and has been validated in Turkish.
The total score is between 0 and 40.
Higher scores indicate OAB symptom burden and severity.
|
Baseline
|
|
Three-day bladder diary (BD)
Time Frame: Baseline
|
BD contains the most critical parameters for measuring the frequency and severity of LUTS according to International Continence Society (ICS) recommendations and definitions.
The 3-day bladder diary measures the frequency of urination, nocturia, urgency, and urge incontinence for 3 consecutive days.
The average frequency of each symptom over three days will be considered the final result.
|
Baseline
|
|
King's Quality of Life Questionnaire (KHQ)
Time Frame: Baseline
|
One of the commonly used quality of life measures for urinary dysfunction is the King's Quality of Life Questionnaire.
It is one of the most valid and widely used questionnaires that targets the quality of life in patients with urinary incontinence and precisely measures the impact of urinary incontinence symptoms on the quality of life.
|
Baseline
|
|
Incontinence Severity Index (ISI)
Time Frame: Baseline
|
Developed for use in epidemiological and clinical studies to identify women suffering from urinary incontinence, ISI, used in many different urinary incontinence studies, consists of two questions and the total score obtained by multiplying the frequency of urinary incontinence and the amount of urinary incontinence varies between 1 and 12.
|
Baseline
|
|
Neurogenic Bladder Symptom Score (NBSS)
Time Frame: Baseline
|
The Neurogenic Bladder Symptom Score (NBSS) is a discriminatory tool developed for use in patients with spinal cord injuries, multiple sclerosis, and spina bifida.
There are a total of 22 questions covering incontinence, storage and voiding symptoms, as well as urinary complications associated with neurogenic bladder dysfunction.
|
Baseline
|
|
Overactive bladder form (OAB-v8)
Time Frame: After the 6-week intervention
|
OAB-v8 is an eight-item screening test for overactive bladder (OAB) symptoms and has been validated in Turkish.
The total score is between 0 and 40.
Higher scores indicate OAB symptom burden and severity.
|
After the 6-week intervention
|
|
Three-day bladder diary (BD)
Time Frame: After the 6-week intervention
|
BD contains the most critical parameters for measuring the frequency and severity of LUTS according to International Continence Society (ICS) recommendations and definitions.
The 3-day bladder diary measures the frequency of urination, nocturia, urgency, and urge incontinence for 3 consecutive days.
The average frequency of each symptom over three days will be considered the final result.
|
After the 6-week intervention
|
|
King's Quality of Life Questionnaire (KHQ)
Time Frame: After the 6-week intervention
|
One of the commonly used quality of life measures for urinary dysfunction is the King's Quality of Life Questionnaire.
It is one of the most valid and widely used questionnaires that targets the quality of life in patients with urinary incontinence and precisely measures the impact of urinary incontinence symptoms on the quality of life.
|
After the 6-week intervention
|
|
Incontinence Severity Index (ISI)
Time Frame: After the 6-week intervention
|
Developed for use in epidemiological and clinical studies to identify women suffering from urinary incontinence, ISI, used in many different urinary incontinence studies, consists of two questions and the total score obtained by multiplying the frequency of urinary incontinence and the amount of urinary incontinence varies between 1 and 12.
|
After the 6-week intervention
|
|
Neurogenic Bladder Symptom Score (NBSS)
Time Frame: After the 6-week intervention
|
The Neurogenic Bladder Symptom Score (NBSS) is a discriminatory tool developed for use in patients with spinal cord injuries, multiple sclerosis, and spina bifida.
There are a total of 22 questions covering incontinence, storage and voiding symptoms, as well as urinary complications associated with neurogenic bladder dysfunction.
|
After the 6-week intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Jacomo RH, Alves AT, Lucio A, Garcia PA, Lorena DCR, de Sousa JB. Transcutaneous tibial nerve stimulation versus parasacral stimulation in the treatment of overactive bladder in elderly people: a triple-blinded randomized controlled trial. Clinics (Sao Paulo). 2020 Jan 10;75:e1477. doi: 10.6061/clinics/2020/e1477. eCollection 2020.
- Marzouk MH, Darwish MH, El-Tamawy MS, Morsy S, Abbas RL, Ali AS. Posterior tibial nerve stimulation as a neuromodulation therapy in treatment of neurogenic overactive bladder in multiple sclerosis: A prospective randomized controlled study. Mult Scler Relat Disord. 2022 Dec;68:104252. doi: 10.1016/j.msard.2022.104252. Epub 2022 Oct 17.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 20, 2023
Primary Completion (Actual)
October 20, 2025
Study Completion (Actual)
October 30, 2025
Study Registration Dates
First Submitted
November 16, 2023
First Submitted That Met QC Criteria
November 16, 2023
First Posted (Actual)
November 22, 2023
Study Record Updates
Last Update Posted (Estimated)
December 4, 2025
Last Update Submitted That Met QC Criteria
November 26, 2025
Last Verified
November 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Neurogenic Bladder
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on TTNS (Transcutaneous tibial nerve stimulation)
-
Pamukkale UniversityNot yet recruitingUrinary Bladder, OveractiveTurkey
-
University of ZurichTerminatedNeurogenic Bladder DysfunctionSwitzerland
-
Oregon Health and Science UniversityAmerican Urogynecologic SocietyRecruitingOveractive BladderUnited States
-
University Hospital, GhentTerminatedOveractive Bladder SyndromeBelgium
-
Kaiser PermanenteAmerican Urogynecologic SocietyActive, not recruitingOveractive Bladder | Urge IncontinenceUnited States
-
University of Texas Southwestern Medical CenterRecruiting
-
Cairo UniversityNot yet recruitingPrimary DysmenorrheaEgypt
-
Pamukkale UniversityNot yet recruitingUrinary Bladder, OveractiveTurkey
-
DJO UK LtdNot yet recruitingOveractive Bladder (OAB) | Refractory Overactive Bladder | Urinary Urgency and FrequencyFrance
-
Pamukkale UniversityNot yet recruitingUrinary Bladder, OveractiveTurkey